Search Results
Staff
Dr. Philip Shaw was an investigator in the Social and Behavioral Research Branch at the National Human Genome Research Institute.
​
… Next we use these heritable brain phenotypes for both gene discovery (through GWAS) and gene understanding. Translational studies:  We are attempting … Genome Research Institute. … Philip Shaw, gene-environment interactions, attention deficit hyperactivity disorder, ADHD, …
For Health Professionals
The Inter-Society Coordinating Committee for Practitioner Education in Genomics (ISCC-PEG) aims to improve genomic literacy of healthcare providers and enhance the effective practice of genomics-informed healthcare by facilitating interactions among the key stakeholders in genomics education.
… practice of genomics-informed healthcare by facilitating interactions among the key stakeholders in genomics … practice of genomics-informed healthcare by facilitating interactions among the key stakeholders in genomics … practice of genomics-informed healthcare by facilitating interactions among the key stakeholders in genomics …
Event
On March 15, 2021, NHGRI’s Policy and Program Analysis Branch hosted a panel discussion exploring a constant tension at multiple levels in genomics research and medicine, from patient-provider interactions to research engagement with marginalized communities.
… in genomics research and medicine, from patient-provider interactions to research engagement with marginalized … in genomics research and medicine, from patient-provider interactions to research engagement with marginalized … in genomics research and medicine, from patient-provider interactions to research engagement with marginalized …
Educational Resources
A stop codon is a trinucleotide sequence within a messenger RNA (mRNA) molecule that signals a halt to protein synthesis.
… … Amino Acids, Cell, Codon, Deoxyribonucleic Acid (DNA), Gene Environment Interaction, Genetic Code, Messenger RNA (mRNA), Protein, Translation, Gene … A stop codon is a sequence of three nucleotides (a …
Event
NHGRI, National Institute of Environmental Health Sciences (NIEHS) and National Cancer Institute (NCI) will host a pre-application interactive webinar for the Multi-Omics for Health and Disease program funding opportunity announcements (FOAs): RFA-HG-22-008,
RFA-HG-22-009 and RFA-HG-22-010.
About Genomics
In 2003, an accurate and complete human genome sequence was finished two years ahead of schedule and at a cost less than the original estimated budget.
… Project covers about 99 percent of the human genome's gene-containing regions, and it has been sequenced to an … 30,000 STSs 52,000 STSs October 1998 DNA Sequence 95% of gene-containing part of human sequence finished to 99.99% … Variations, Phenotypes, Large-scale Protein-protein Interactions, Data Sets Of Sequence And Variation … In 2003, …
Policies and Guidance
Guidance describing NHGRI’s position on appropriate third-party involvement.
… third-party involvement. It applies to post-award interactions with third parties; pre-award interactions are …  If support from the third party is in the form of a drug, device, or biologic, the third party will ensure the … events reasonably attributable to the intervention, drug, device, or biologic.  The third party agrees to not …
Careers and Training
NHGRI provides funding to support the development and implementation of modules aimed at providing healthcare professionals with genomic medicine training.
… We will discuss clinically actionable pharmacogenomic gene-drug pairs across a variety of diseases, such as oncology, …
Event
On February 16, 2023, the National Human Genome Research Institute (NHGRI) held a follow-up working group consultation after the 14th Genomic Medicine meeting, Genomic Medicine XIV: Genomic Learning Healthcare Systems.
… It almost never gets used. We have CDS for >30 gene-drug pairs in our EHR; this may be relevant, but is not … consultservice. We have a physician who is expert in drug interactions and PGx, Tom Callaghan, M.D., Ph.D., who has a …
15 Ways Genomics Influences Our World
Genomics is helping us choose the right medication at the right dose for each patient.
… that this was due to genomic variants in the HLA-B  gene . Not surprisingly, this gene helps control the immune … more people. That's why at this time, the U.S. Food and Drug Administration (FDA) labeling for tamoxifen does not … develops, more and more clinical trials will test for interactions between our genomes and the medicines we take. …